You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
New studies suggest levels of a blood protein that may reflect whether someone has Alzheimer's disease.
Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
The WGS analysis placed the triple-negative breast cancers into three groups, each of which had different treatment responses and prognoses.
Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.
New study finds bias against female lecturers among student course evaluations, the Economist reports.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.
In the study, the partners will perform exome sequencing and whole-genome array genotyping on more than 9,000 individuals with diabetes or with diabetic relatives.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.